By Patrick Wingrove and Maggie Fick (Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing capacity and ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

Shares of Novo Nordisk closed around 1% lower on Thursday, while Eli Lilly's stock closed more than 11% lower. It comes as Novo Nordisk works to boost access ... across the US healthcare system ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for ...

A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...

The MOU marks a significant step in strengthening the Kingdom’s healthcare sector and pharmaceutical manufacturing ... at Novo Nordisk. “By localizing production, we are enhancing access to our ...

Novo Nordisk has gone up another gear in its drive to boost manufacturing ... injectables in North Carolina, US. The new plant will be one of the largest manufacturing investments in Novo Nordisk ...

Oral pills, being more convenient than injectables, tend to boost patient adherence. Novo Nordisk also markets Rybelsus ... of the obesity market makes us believe that the setback is temporary.